Investigational New Drugs

Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression
pp. 3-9(7)
Authors: Medina-Gundrum, Leticia; Cerna, Cesario; Gomez, Lionel; Izbicka, Elzbieta

Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions
pp. 11-20(10)
Authors: Lansky, Ephraim P.; Jiang, Wenguo; Mo, Huanbiao; Bravo, Lou; Froom, Paul; Yu, Weiping; Harris, Neil M.; Neeman, Ishak; Campbell, Moray J.

Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123
pp. 21-29(9)
Authors: Si, Ming-Sing; Reitz, Bruce A.; Borie, Dominic C.

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
pp. 31-37(7)
Authors: Marshall, John L.; Kindler, Hedy; Deeken, John; Bhargava, Pankaj; Vogelzang, Nicholas J.; Rizvi, Naiyer; Luhtala, Taina; Boylan, Stacy; Dordal, Margaret; Robertson, Philmore; Hawkins, Michael J.; Ratain, Mark J.

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
pp. 39-49(11)
Authors: Bence, Aimee K.; Anderson, Eric B.; Halepota, Maqbool A.; Doukas, Michael A.; DeSimone, Phillip A.; Davis, George A.; Smith, Deborah A.; Koch, Kevin M.; Stead, Andrew G.; Mangum, Steve; Bowen, Carolyn J.; Spector, Neil L.; Hsieh, Showchien; Adams, Val R.

Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)
pp. 51-56(6)
Authors: Bjarnason, Georg; Charpentier, Danielle; Wong, Ralph; Goel, Rakesh; Douglas, Lynn; Walsh, Wendy; Matthews, Sarah; Dent, Susan; Seymour, Lesley

Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors
pp. 57-62(6)
Authors: El-Rayes, Basil F.; Ibrahim, Dina; Shields, Anthony F.; LoRusso, Patricia M.; Zalupski, Mark M.; Philip, Philip A.

An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin
pp. 63-71(9)
Authors: Goel, R.; Chouinard, E.; Stewart, D. J.; Huan, S.; Hirte, H.; Stafford, S.; Waterfield, B.; Roach, J.; Lathia, C.; Agarwal, V.; Humphrey, R.; Walsh, W.; Matthews, S.; Seymour, L.

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
pp. 73-77(5)
Authors: Chang, Gee-Chen; Chen, Kun-Chieh; Yang, Tsung-Ying; Yin, Ming-Chang; Lin, Ching-Pei; Kuo, Benjamin Ing-Tiau; Hsu, Jeng-Yuan

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)
pp. 79-84(6)
Authors: Latif, Tahir; Wood, Laura; Connell, Cindy; Smith, David C.; Vaughn, David; Lebwohl, David; Peereboom, David

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer
pp. 85-89(5)
Authors: Caponigro, Francesco; Willemse, Pax; Sorio, Roberto; Floquet, Anne; van Belle, Simon; Demol, Jan; Tambaro, Rosa; Comandini, Alessandro; Capriati, Angela; Adank, Sabine; Wanders, Jantien